Patents by Inventor Rolf Larsson
Rolf Larsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11504356Abstract: The invention provides mebendazole for use in the treatment or prophylaxis of a chronic inflammatory disease, and in particular wherein the chronic inflammatory disease is an autoimmune disease, for example sarcoidosis, systemic lupus erythematosus (SLE), Huntington's disease, end stage renal disease, systemic sclerosis (also called scleroderma), myositis, diabetes type 1, multiple sclerosis, Sjögren's syndrome, rheumatoid arthritis, psoriasis, primary biliary cirrhosis, autoimmune hepatitis, Graves' disease, Addison's disease, tuberculosis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, Alzheimer's disease and coeliac disease. A method for the treatment or prophylaxis of a chronic inflammatory disease, comprising administering an effective amount of a mebendazole or a pharmaceutical composition of mebendazole is also provided. The use of mebendazole for the manufacture of a medicament for the treatment of a chronic inflammatory disease is also provided.Type: GrantFiled: December 19, 2018Date of Patent: November 22, 2022Assignee: REPOS PHARMA ABInventors: Marten Fryknas, Rolf Larsson, Peter Nygren
-
Publication number: 20220241836Abstract: Device for shaping a component, comprising a first tool and a second tool, which can be moved relative to one another along a movement axis to shape a component to be placed between the tools, wherein a surface of the first tool can be extended transverse to the movement axis in an extension region. With the described device and with the described method, components, in particular sheet steel components, can be shaped in such a way that contours that are oriented in parallel to a movement axis of the tools are particularly well formed. In particular circular shapes can thus be formed with particularly good accuracy. Negative influences of fluctuations of the thickness of the component can be offset. The device and the method are particularly suitable for the production of wheel rims for motor vehicles.Type: ApplicationFiled: April 29, 2020Publication date: August 4, 2022Inventor: Jan Rolf Larsson
-
Publication number: 20210015797Abstract: The invention provides mebendazole for use in the treatment or prophylaxis of a chronic inflammatory disease, and in particular wherein the chronic inflammatory disease is an autoimmune disease, for example sarcoidosis, systemic lupus erythematosus (SLE), Huntington's disease, end stage renal disease, systemic sclerosis (also called scleroderma), myositis, diabetes type 1, multiple sclerosis, Sjögren's syndrome, rheumatoid arthritis, psoriasis, primary biliary cirrhosis, autoimmune hepatitis, Graves' disease, Addison's disease, tuberculosis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, Alzheimer's disease and coeliac disease. A method for the treatment or prophylaxis of a chronic inflammatory disease, comprising administering an effective amount of a mebendazole or a pharmaceutical composition of mebendazole is also provided. The use of mebendazole for the manufacture of a medicament for the treatment of a chronic inflammatory disease is also provided.Type: ApplicationFiled: December 19, 2018Publication date: January 21, 2021Applicant: REPOS PHARMA ABInventors: Marten FRYKNAS, Rolf LARSSON, Peter NYGREN
-
Patent number: 10022380Abstract: A cell permeable iron chelator, optionally in combination with an autophagy inhibiting agent, is used for treating a solid cancer tumor in a person. A preferred chelator is an alkyl substituted N-(1-pyridine-2-yl-methylidene)-N-(9H-1,3,4,9-tetraaza-fluoren-2-yl)-hydrazine. A preferred autophagy inhibiting agent is chloroquine. Also disclosed is a pharmaceutical composition comprising iron chelator, pharmaceutically acceptable carrier and, optionally, autophagy inhibiting agent; and a method of treating cancer by administering cancer combating-effective amount(s) of the iron chelator or the combination of iron chelator and autophagy inhibiting agent.Type: GrantFiled: June 16, 2017Date of Patent: July 17, 2018Assignee: VIVOLUX ABInventors: Stig Linder, Mårten Fryknäs, Rolf Larsson
-
Patent number: 9856511Abstract: A method for screening a compound to determine whether the compound is a proteasome deubiquitinating inhibitor of high specificity comprises contacting the compound with human 19S regulatory particles (19S RP) of 26S proteasome and determining whether the compound inhibits activity of deubiquitinating (DUB) enzymes UCHL5 and USP14; inhibition of UCHL5 and USCP14 activities indicates that the compound is a proteasome deubiquitinating inhibitor of high specificity.Type: GrantFiled: September 6, 2012Date of Patent: January 2, 2018Assignee: VIVOLUX ABInventors: Slavica Brnjic, Padraig D'Arcy, Rolf Larsson, Stig Linder
-
Publication number: 20170348317Abstract: A cell permeable iron chelator, optionally in combination with an autophagy inhibiting agent, is used for treating a solid cancer tumour in a person. A preferred chelator is an alkyl substituted N-(1-pyridine-2-yl-methylidene)-N-(9H-1,3,4,9-tetraaza-fluoren-2-yl)-hydrazine. A preferred autophagy inhibiting agent is chloroquine. Also disclosed is a pharmaceutical composition comprising iron chelator, pharmaceutically acceptable carrier and, optionally, autophagy inhibiting agent; and a method of treating cancer by administering cancer combating-effective amount(s) of the iron chelator or the combination of iron chelator and autophagy inhibiting agent.Type: ApplicationFiled: June 16, 2017Publication date: December 7, 2017Inventors: Stig Linder, Mårten Fryknäs, Rolf Larsson
-
Aqueous solution comprising a macromolecular conjugate of heparin for the treatment of blood vessels
Patent number: 9795629Abstract: The present invention relates to a solution for treating blood vessels where the solution comprises a heparin conjugate. The invention further relates to the use of the conjugate as a medicament and a method of coating tissue using the conjugate.Type: GrantFiled: December 17, 2012Date of Patent: October 24, 2017Assignee: CORLINE SYSTEMS ABInventor: Rolf Larsson -
Patent number: 9446476Abstract: Backing arrangement for supporting a welded seam extending on a curved path which is formed between two curved work pieces by friction stir welding with a welding tool separate from the backing arrangement, which backing arrangement comprises a backing body which is intended to bear upon the work pieces opposite said welding tool to assume at least a part of the compression force that is exerted by the welding tool against the work pieces to keep the material plasticized during the welding operation in the area of the welded seam The backing body is equipped with a shoulder which exhibits a bottom surface turned outward, via which the backing body is equipped to bear on the work pieces. A driving mechanism is situated to rotate and/or oscillate the shoulder so that the bottom surface of the shoulder can thereby be made to carry out a rotating and/or oscillating motion against the work pieces for creating fictional heat in them.Type: GrantFiled: February 9, 2012Date of Patent: September 20, 2016Assignee: ESAB ABInventor: Rolf Larsson
-
Patent number: 9221761Abstract: Compounds of the general structure S-1, wherein X and R1-R5 are defined in the specification, are capable of abrogating the deubiquitinating (DUB) activity of the 19S RP DUBs and are useful in methods and compositions for treating cancer, in particular, cancer tumors refractory to treatment by state-of-the-art chemotherapy.Type: GrantFiled: April 18, 2014Date of Patent: December 29, 2015Assignee: Vivolux ABInventors: Stig Linder, Rolf Larsson
-
Publication number: 20150328714Abstract: Backing arrangement (2) for supporting a welded seam extending on a curved path which is formed between two curved work pieces by friction stir welding with a welding tool separate from the backing arrangement, which backing arrangement comprises a backing body (20) which is intended to bear upon the work pieces opposite said welding tool to assume at least a part of the compression force that is exerted by the welding tool against the work pieces to keep the material plasticized during the welding operation in the area of the welded seam. The backing body is equipped with a shoulder (21) which exhibits a bottom surface (22) turned outward, via which the backing body is equipped to bear on the work pieces. A driving mechanism (50) is situated to rotate and/or oscillate the shoulder so that the bottom surface of the shoulder can thereby be made to carry out a rotating and/or oscillating motion against the work pieces for creating fictional heat in them.Type: ApplicationFiled: February 9, 2012Publication date: November 19, 2015Applicant: ESAB ABInventor: Rolf Larsson
-
Publication number: 20140370528Abstract: A method for screening a compound to determine whether the compound is a proteasome deubiquinating inhibitor of high specificity comprises contacting the compound with human 19S regulatory particles (19S RP) of 26S proteasome and determining whether the compound inhibits activity of deubiquinating (DUB) enzymes UCHL5 and USP14; inhibition of UCHL5 and USCP14 activities indicates that the compound is a proteasome deubiquinating inhibitor of high specificity.Type: ApplicationFiled: September 6, 2012Publication date: December 18, 2014Applicant: Vivolux ABInventors: Slavica Brnjic, Padraig D'Arcy, Rolf Larsson, Stig Linder
-
AQUEOUS SOLUTION COMPRISING A MACROMOLECULAR CONJUGATE OF HEPARIN FOR THE TREATMENT OF BLOOD VESSELS
Publication number: 20140349963Abstract: The present invention relates to a solution for treating blood vessels where the solution comprises a heparin conjugate. The invention further relates to the use of the conjugate as a medicament and a method of coating tissue using the conjugate.Type: ApplicationFiled: December 17, 2012Publication date: November 27, 2014Applicant: CORLINE SYSTEMS ABInventor: Rolf Larsson -
Publication number: 20140228354Abstract: Compounds of the general structure S-1, wherein X and R1-R5 are defined in the specification, are capable of abrogating the deubiquitinating (DUB) activity of the 19S RP DUBs and are useful in methods and compositions for treating cancer, in particular, cancer tumors refractory to treatment by state-of-the-art chemotherapy.Type: ApplicationFiled: April 18, 2014Publication date: August 14, 2014Applicant: Vivolux ABInventors: Stig Linder, Rolf Larsson
-
Publication number: 20140073645Abstract: A cell permeable iron chelator, optionally in combination with an autophagy inhibiting agent, is used for treating a solid cancer tumour in a person. A preferred chelator is an alkyl substituted N-(1-pyridine-2-yl-methylidene)-N-(9H-1,3,4,9-tetraaza-fluoren-2-yl)-hydrazine. A preferred autophagy inhibiting agent is chloroquine. Also disclosed is a pharmaceutical composition comprising iron chelator, pharmaceutically acceptable carrier and, optionally, autophagy inhibiting agent; and a method of treating cancer by administering cancer combating-effective amount(s) of the iron chelator or the combination of iron chelator and autophagy inhibiting agent.Type: ApplicationFiled: March 14, 2012Publication date: March 13, 2014Applicant: VIVOLUX ABInventors: Stig Linder, Märten Fryknas, Rolf Larsson
-
Publication number: 20120309798Abstract: N1-(3-Methoxypropyl)-2-(pyridylmethylidene)-hydrazine-1-carbothioamide (I) and its Cu2+, Pd2+ and Pt2+ complexes are effective anti-tumor agents. Also disclosed are compositions comprising (I) and its Cu2+, Pd2+ and Pt2+ complexes, and the use of the compositions in the treatment of malignant tumors.Type: ApplicationFiled: December 8, 2010Publication date: December 6, 2012Inventors: Rolf Larsson, Peter Nygren, Joakim Gullbo, Gunnar Westman
-
Patent number: 8323986Abstract: The present invention relates to a molecular assembly on a substrate usable for studying and/or performing biological interactions and/or reactions The invention further relates to an in vitro method to provide a substrate with a heparin coating presenting biotinylated biomolecules comprising linking avidin to a surface capable of binding avidin. A heparin conjugate is then linked to the avidin treated surface to form a layer of heparin thereon. Finally, a biotinylated biological probe or biomolecule is linked to the avidin through the layer of heparin thereby forming an essentially biologically inert surface with biotinylated probes extending out from the surface.Type: GrantFiled: September 28, 2007Date of Patent: December 4, 2012Assignee: Corline Systems ABInventors: Javier Sanchez, Rolf Larsson
-
Patent number: 8153147Abstract: The present invention discloses an in vitro method to provide biological tissue with a heparin coating comprising the following steps; linking a biotin reagent to biological tissue, linking an avidin reagent to the biotinylated biological tissue, and linking a heparin reagent to the formed layer of avidin on the biological tissue thus forming a heparin coating. The invention further discloses a heparin coating on biological tissue, the use of a heparin coating, and the biological tissue coated with a heparin layer according to the method.Type: GrantFiled: June 28, 2006Date of Patent: April 10, 2012Assignee: Corline Systems ABInventor: Rolf Larsson
-
Patent number: 7981873Abstract: The present invention is within the field of transplantation surgery. More closely, the present invention relates to use of a clotting preventing agent in the production of a drug for administration in association with transplantation of insulin producing cells in the form of isolated islets to patients with insulin dependent diabetes mellitus, IDDM. The invention is expected to significantly improve the clinical outcome of transplantation of islets of Langerhans.Type: GrantFiled: February 4, 2000Date of Patent: July 19, 2011Assignee: Corline Systems ABInventors: Olle Korsgren, William Bennet, Bo Nilsson, Rolf Larsson
-
Publication number: 20100269957Abstract: A high-strength product of sheet steel is produced in the press hardening process. A blank is heated to reach austenite structure and hot-stamped in a pair of cooled tools. The product is kept in the tools to rapidly be cooled to harden with the tools as a fixture. The blank has a surface of black oxide before it is shaped and the shaped product is painted directly on the black surface.Type: ApplicationFiled: November 11, 2008Publication date: October 28, 2010Inventors: Paul Akerstrom, Jan Rolf Larsson
-
Publication number: 20100178657Abstract: The present invention relates to a molecular assembly on a substrate usable for studying and/or performing biological interactions and/or reactions The invention further relates to an in vitro method to provide a substrate with a heparin coating presenting biotinylated biomolecules comprising linking avidin to a surface capable of binding avidin. A heparin conjugate is then linked to the avidin treated surface to form a layer of heparin thereon. Finally, a biotinylated biological probe or biomolecule is linked to the avidin through the layer of heparin thereby forming an essentially biologically inert surface with biotinylated probes extending out from the surface.Type: ApplicationFiled: September 28, 2007Publication date: July 15, 2010Inventors: Javier Sanchez, Rolf Larsson